Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

BriaCell

TSX:BCT

Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients

Featured Articles and Interviews
Press Releases

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer


Overview

BriaCell Therapeutics (NASDAQ:BCTX, BCTXW;TSX:BCT) is a clinical-phase biotechnology company developing innovative immunotherapies for treating cancer.

At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Immunotherapies also have low-toxicity, making it easier for patients to undergo treatment. Most importantly, they may offer better efficacy and less chance of recurrence for many cancer patients. A report released by Research and Markets says the global immuno-oncology market is expected to reach US$135 billion by 2024. BriaCell continues to uncover opportunities in this space with its innovative technologies.

Interactive Chart

×